Furthermore, treating B16F10-bearing mice with a DC vaccine using anti-DEC-205-hgp100 in combination with the anti-Tim-3 antibody led to significantly reduced tumor growth compared with treatment with the DC vaccine alone, thus identifying the β-catenin-Tim-3 pathway as a new target for therapeutic intervention. The gene discussed is HAVCR2; the disease is neoplasm.